Scroll for more
news Apr 13, 2017

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Pharmaphorum highlights how this “data mining angle to identify potential new drug targets is one area of particular interest to the pharmaceutical industry.” Working with MRC Technology, we’ll be sharing targets identified through our AI system, which they will then use to carry out any pre-clinical and clinical development of the compound. MRC Technology will also run molecules and antibodies though BenevolentAI’s deep learning platform to validate them. Click through to the article for more information.